A Phase II Trial Combining Personalized Neoantigen Peptide Vaccines with Precision Radiotherapy for Advanced Cancers | Research

The takeaway

This Phase II trial is testing whether combining personalized cancer vaccines made from tumor-specific peptides with targeted radiotherapy can improve outcomes in advanced cancer patients who've failed standard treatment.

Phase II randomized with crossover
One of the few neoantigen vaccine trials using a randomized placebo-controlled design with crossover, providing higher-quality evidence than typical single-arm studies

What the researchers found

This is a trial protocol rather than a results paper. The study introduces a novel combination of individualized neoantigen peptide vaccines with critical lesion radiotherapy (CLERT) for stage IV cancer patients across multiple tumor types.

Key design features include a randomized 1:1 allocation with placebo control (rare in neoantigen trials), a crossover design allowing placebo patients to switch to the vaccine arm upon progression, and a basket-trial framework that leverages shared neoantigens across cancer types. The primary endpoints are progression-free survival and objective response rate.

Why it matters

Neoantigen vaccines are one of the most personalized cancer treatments possible — they're designed from each patient's own tumor mutations. But in advanced cancers, they haven't worked well alone because the immune system is too suppressed and tumor burden too high. This trial tests a promising solution: using targeted radiation to prime the immune system before vaccination, potentially making the vaccine far more effective in patients with few options left.

How the study worked

This is an open-label, multicenter Phase II randomized trial. Patients with advanced solid tumors (including melanoma, glioblastoma, lung cancer, and colorectal cancer) who have failed first-line therapy are randomized 1:1 to receive either personalized neoantigen peptide vaccine plus conventional treatment (with high and low dose radiotherapy) or placebo plus conventional treatment. A one-way crossover lets placebo patients switch to the vaccine arm if their disease progresses. Patients must have at least one predicted high-quality tumor neoantigen, an ECOG score of 0-2, and projected survival of at least 3 months.

What this study cannot tell us

No results are available yet — this is a protocol description only. The open-label design means patients and doctors know who is receiving the vaccine, which could influence assessments. Manufacturing personalized vaccines requires tumor sequencing and neoantigen prediction, which may not be accessible outside major medical centers. The crossover design, while ethical, may complicate interpretation of overall survival data.

How to read the evidence

This is a trial protocol with no results reported yet. It describes the design and rationale for a Phase II study. While the design is rigorous for this field, no efficacy or safety data are available to evaluate.

When this study was published

Published in 2025, this is a current trial protocol. Results are pending and will be critical for assessing whether this combination approach works in advanced cancer patients.

The bigger picture

Personalized cancer vaccines have generated excitement but have hit a wall in late-stage disease. This trial represents the broader push to combine immunotherapy with other modalities — in this case, using radiation not just to kill tumors but to make them more visible to the immune system. The basket-trial design across multiple cancer types also reflects a shift toward mutation-based rather than organ-based cancer treatment, which could make personalized vaccines more practical and affordable at scale.

Questions still open

Will the combination of radiation and neoantigen vaccines produce measurably better responses than either treatment alone in stage IV patients?
Can the basket-trial approach using shared neoantigens across cancer types actually reduce vaccine preparation time and cost?
How will the crossover design affect the ability to measure true survival benefit from the vaccine?

Common questions

What is a neoantigen peptide vaccine?

It's a vaccine made from short protein fragments (peptides) that are unique to a patient's own tumor. Because these neoantigens come from cancer-specific mutations not found in normal cells, the vaccine trains the immune system to recognize and attack the cancer without harming healthy tissue. Each vaccine is custom-manufactured for the individual patient.

Why combine the vaccine with radiation?

In advanced cancer, the immune system is often too suppressed to respond well to a vaccine alone. Targeted radiation can damage tumor cells and release their contents, essentially creating a 'crime scene' that alerts the immune system. This radiation-induced immune activation may prime the body to respond much more strongly when the neoantigen vaccine is given.

Read the original research

A phase II randomized trial of individualized neoantigen peptide vaccine combined with unusual radiotherapy (iNATURE) in advanced solid tumors-GCOG0028.

Frontiers in immunology, 16, 1538032

View on PubMed ↗Publisher’s paper ↗

Citation

Zhang, Yan; Hu, Ye-Fan; Ma, Lingyu; Wu, Yifei; Chao, Dandan; Chen, Xian; Xu, Zhiyuan; Su, Xiaoping; Dai, Wei; Huang, Jiandong; Fu, Pingfu; Kong, Feng-Ming Spring. (2025). A phase II randomized trial of individualized neoantigen peptide vaccine combined with unusual radiotherapy (iNATURE) in advanced solid tumors-GCOG0028.. Frontiers in immunology, 16, 1538032. https://doi.org/10.3389/fimmu.2025.1538032